Quick Takeaways
- JPMORGAN CHASE & CO filed SCHEDULE 13G for LB Pharmaceuticals Inc Common Stock, $0.0001 par value (LBRX).
- Disclosed ownership: 6.3%.
- Date of event: 31 Dec 2025.
JPMORGAN CHASE & CO - 31 Dec 2025 SCHEDULE 13G Report for LB Pharmaceuticals Inc Common Stock, $0.0001 par value (LBRX)
- Filing Manager
- JPMORGAN CHASE & CO
- Reporting Manager
- JPMORGAN CHASE & CO.
- Symbol
- LBRX
- Shares outstanding
- 25,579,079 shares
- Disclosed Ownership
- 1,611,482 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13G
- Filing time
- 21 Jan 2026, 08:13:39 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JPMORGAN CHASE & CO disclosed 6.3% ownership in LB Pharmaceuticals Inc Common Stock, $0.0001 par value (LBRX) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 21 Jan 2026, 08:13.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO. | 6.3% | 1,611,482 | 1,471,295 | 0 | Rachel Tsvaygoft | Vice President |